Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropidoxuridine - Shuttle Pharmaceuticals

Next Previous
Drug Profile

Ropidoxuridine - Shuttle Pharmaceuticals

Alternative Names: 5-Iodo-2-pyrimidinone 2'' deoxyribonucleoside; 5-Iodo-2-pyrimidinone-2''-deoxyribose; IMRT; Intensity Modulated RT; Intensity-Modulated Radiotherapy; IPdR - Shuttle Pharmaceuticals; Ropidoxuridine-Shuttle-Pharmaceuticals

Latest Information Update: 21 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shuttle Pharmaceuticals
  • Developer National Cancer Institute (USA); Shuttle Pharmaceuticals
  • Class Antineoplastics; Antivirals; Pyrimidine nucleosides; Radiation-sensitising agents; Small molecules
  • Mechanism of Action DNA inhibitors; DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal cancer; Glioblastoma; Sarcoma

Most Recent Events

  • 08 Jan 2024 Shuttle Pharmaceuticals received safe to proceed letter for ropidoxuridine in Glioblastoma
  • 11 Dec 2023 Shuttle Pharmaceuticals files an IND application with the US FDA for phase-II trial for Glioblastoma
  • 25 Sep 2023 Shuttle Pharmaceuticals receives positive feedback from FDA for a Type B pre-Investigational New Drug Application (PIND) meeting in Glioblastoma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top